I was reading this morning about a new obesity drug that has Wall Street analysts gravely disappointed. It seems that after years of clinical trials, the drug passed two of three important tests with flying colors. It helped lower cholesterol and, if that wasn’t enough, it didn’t appear to cause heart-valve failure. It sounds like a winner so far.

The one test it failed, however, was a doozy. The weight-loss drug did not result in people actually losing weight.

Show Comments Hide Comments


Sign up for Inman’s Morning Headlines
What you need to know to start your day with all the latest industry developments
Thank you for subscribing to Morning Headlines.
Back to top